Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer
نویسندگان
چکیده
منابع مشابه
Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
Degarelix, approved in the USA in 2008, is a gonadotropin-releasing hormone antagonist, representing one of the latest additions to androgen deprivation therapy (ADT). ADT is used as first-line therapy for locally advanced or metastatic prostate cancer with the aim to reduce testosterone to castrate levels. Like other gonadotropin-releasing hormone-antagonists, degarelix treatment results in ra...
متن کاملQuality of life improvement in patients treated with degarelix versus leuprorelin for advanced prostate cancer.
PURPOSE We used responses to questionnaires included in the CS21 degarelix trial and published mapping algorithms to address the paucity of evidence for health related quality of life in patients with advanced hormone dependent prostate cancer treated with degarelix. MATERIALS AND METHODS We measured health related quality of life in 610 patients enrolled in the CS21 trial using SF-12® and EO...
متن کاملDegarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis
Background: Hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. We performed a systematic review to compare safety, efficacy and effectiveness of degarelix, a new gonadotropin-releasing hormone (GnRH) antagonist (blocker), versus gonadotropin-releasing hormone (GnRH) agonists. Methods: MEDLINE, Web of Science and the Cochrane librar...
متن کاملResponse to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer
J Adv Pract Oncol 2012;3:299–303 Androgen-deprivation therapy (ADT) is a common treatment for prostate cancer, as the androgen receptor (AR) plays a role in the development of this malignancy. Androgen-deprivation therapy agents can be classified as gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists. The most common GnRH agents in use are the GnRH agonists. However, these agents...
متن کاملdegarelix for the treatment of advanced prostate cancer compared with gnrh-agonists: a systematic review and meta-analysis
background: hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. we performed a systematic review to compare safety, efficacy and effectiveness of degarelix, a new gonadotropin-releasing hormone (gnrh) antagonist (blocker), versus gonadotropin-releasing hormone (gnrh) agonists. methods: medline, web of science and the cochrane library w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JACC: CardioOncology
سال: 2020
ISSN: 2666-0873
DOI: 10.1016/j.jaccao.2020.01.004